Hospital-acquired conditions are a strategic focus area for Mölnlycke Health Care, supporting prevention and care protocols with clinical and scientific evidence and a portfolio of products that help deliver better outcomes.
One of the biggest HAC challenges, pressure ulcers (PUs), persists, despite the implementation of prevention strategies. PUs are a common side effect of hospitalization, and while they are treatable, prevention is always preferred – for both total cost-of-care and for outcome-related and patient quality of life reasons. Considerable evidence shows that pressure ulcer prevention is not only possible but also makes a difference to the bottom line and to patient comfort and better outcomes.
The wealth of evidence that has been published in support of pressure ulcer prevention is both positive and overwhelming. Phil Davies, Mölnlycke Health Care's Global Medical Communication Strategy Team Manager, collected all of the evidence and has published a definitive review of the abundant material. The monograph, "The role of foam dressings with Safetac® in the prevention of pressure ulcers: a review of the clinical and scientific data", published in the Journal of Wound Care, comprises a systematic review of the literature from the entire evidence hierarchy and scientific data from laboratory studies.
We have highlighted much of this evidence as it has been published in peer-reviewed journals and presented at international conferences. Much of the evidence and data in existence supports the use of multi-layer foam dressings with Safetac as a prophylactic measure; these have influenced clinical practice guidelines and protocols. The monograph constitutes the first time that all of the evidence has been collected and published in one place.
Please see knowledge article Multi-layer foam dressings with Safetac in pressure ulcer prevention: a review of the evidence to help change clinical practice for more information and to download the monograph.